Charles River Laboratories International

Traded on the St. Petersburg Stock Exchange
Charles River Laboratories International, Inc., is a pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical device and Biotechnology industries.
Charles River Laboratories International stock price chart
vol.
change
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Charles River Laboratories International balance sheet

Report period2018 2019 2020 2021 20222023
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Charles River Laboratories International cash flows

Report period2018 2019 2020 2021 20222023
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
Adjusted Earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS
Adjusted EPS

Charles River Laboratories International multipliers

Report period2018 2019 2020 2021 20222023
P/E
P/E adj.
E/P
E adj./P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Charles River Laboratories International profitability

Report period2018 2019 2020 2021 20222023
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Charles River Laboratories International assets
Charles River Laboratories International cash flows

Charles River Laboratories International shares

TickerNameTypeNominal valueISINPrice
CRL:USCharles River Laboratories International, Inc.Common share-US1598641074$226.8
Charles River Laboratories International news
04.05.2022
Net income of Charles River Laboratories International under GAAP for the 3 months of 2022 was $95.226 million, up 48.9% from $63.935 million in the previous year. Revenue increased 10.8% to $913.929 million from $824.566 million a year earlier.
Source: {source} pictogram ir.criver.com
Pictogram next
06.04.2022
Charles River Laboratories International acquired vivarium rental and service company Explora BioLabs Holdings. The transaction amounted to $295 million. Explora's revenues for 2021 were $38 million.
Source: {source} pictogram ir.criver.com
Pictogram next
16.02.2022
Charles River Laboratories International's GAAP net income for 2021 was $398.837 million, up 9.2% from $365.306 million in the previous year. Revenue increased 21.1% to $3.54 billion from $2.924 billion a year earlier.
Source: {source} pictogram ir.criver.com
Pictogram next
03.11.2021
Charles River Laboratories International's GAAP net income for 9M 2021 was $259.01 million, up 17.1% from $221.116 million in the prior year. Revenue increased 23.5% to $2.635 billion from $2.133 billion a year earlier.
Source: {source} pictogram ir.criver.com
Pictogram next
All Charles River Laboratories International news
General information
Company nameCharles River Laboratories International
Tags#s&p500 index
SectorHealth Care / Health Care Equipment & Services / Health Care Providers & Services / Health Care Services
Business address251 BALLARDVALE ST WILMINGTON MA 01887 781-222-6000
Mailing address251 BALLARDVALE ST WILMINGTON MA 01887
Websitewww.criver.com